The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | Access to bispecifics and CAR-Ts for multiple myeloma in Brazil
Vania Hungria, MD, PhD, Faculty of Medical Sciences of Santa Casa de São Paulo, Brazil, discusses the current access to immunotherapies for multiple myeloma (MM) in Brazil. The approved bispecific antibodies are teclistamab, elranatamab, and talquetamab. The CAR-T therapy ciltacabtagene autoleucel (cilta-cel), approved two years ago, has only recently become commercially available due to access issues. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
